Sofinnova Partners launches €725M crossover fund
Statements (3)
- Neutral
Sofinnova Partners closed a second crossover fund at €725 million for late-stage European biotechs
- Neutral
Sofinnova Partners is launching a €725M 'crossover' fund to support later-stage biotechs.
- Neutral
Sofinnova Partners closed a €725 million crossover II fund